EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium

Jonathan E M O'Donnell iD, Lucy A Hastings iD, Julie N Briody, Christine L Chan iD, Carla Colombo iD, Tonia A Douglas iD, Steven D Freedman, Tanja Gonska iD, Jerry R Greenfield iD, Daniel H Leung, Adeline Y L Lim, Antoinette Moran iD und 9 weitere

Pediatric Pulmonology · 2024-06 · 59 (6) · 1661-1676

DOI: 10.1002/ppul.26970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 12.04.2024. Verfasst von Jonathan E M O'Donnell und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sydney Children's Hospital, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The SHIFT symposium was supported by Vertex Pharmaceuticals, with no involvement in manuscript.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cystic fibrosis (CF) is a life‐shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF‐related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations 1 .

Methods

To discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF‐related diabetes, (4) CF liver disease, (5) CF‐related bone disease, and (6) post‐lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed.

Results

Improved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra‐pulmonary care and reduced morbidity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansDiabetes MellitusLiver DiseasesLung Transplantation

Stichwörter der Autor:innen

cystic fibrosiscystic fibrosis bone diseasecystic fibrosis related diabetescystic fibrosis related liver diseaseexocrine pancreatic diseaseextra‐pulmonary complications cystic fibrosislung transplantnutrition

Substanzen

CFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • Department of Gastroenterology, Sydney Children's Hospital, University of New South Wales, Sydney, Australia.
  • School of Clinical Medicine, Discipline of Pediatrics and Child Health, UNSW Medicine & Health, University of New South Wales, Sydney, Australia.
  • Department of Endocrinology, Sydney Children's Hospital Randwick, Sydney Children's Hospitals Network, Sydney, Australia.
  • Nuclear Medicine, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • University of Colorado Anschutz Medical Center, Aurora, Colorado, USA.
  • Children's Hospital Colorado, Aurora, Colorado, USA.

ORCID-Profile: Jonathan E M O'Donnell, Lucy A Hastings, Christine L Chan, Carla Colombo, Tonia A Douglas, Tanja Gonska, Jerry R Greenfield, Antoinette Moran, Bernadette J Prentice, Melissa S Putman, Michael Trotter, Glen P Westall, Claire E Wainwright, Chee Y Ooi

Förderung

  • The SHIFT symposium was supported by Vertex Pharmaceuticals, with no involvement in manuscript

Zitieren

APA

O'Donnell, J. E. M., Hastings, L. A., Briody, J. N., Chan, C. L., Colombo, C., Douglas, T. A., Freedman, S. D., Gonska, T., Greenfield, J. R., Leung, D. H., Lim, A. Y. L., Moran, A., Prentice, B. J., Putman, M. S., Trotter, M., Tullis, E., Westall, G. P., Verge, C. F., Wainwright, C. E., …, & SHIFT Symposium 2021 (2024). SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium. Pediatric Pulmonology, 59(6), 1661-1676. https://doi.org/10.1002/ppul.26970

Vancouver

O'Donnell JEM, Hastings LA, Briody JN, Chan CL, Colombo C, Douglas TA, et al. SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium. Pediatric Pulmonology. 2024;59(6):1661-1676. doi:10.1002/ppul.26970

BibTeX
@article{ODonnell2024,
  author = {O'Donnell, Jonathan E M and Hastings, Lucy A and Briody, Julie N and Chan, Christine L and Colombo, Carla and Douglas, Tonia A and Freedman, Steven D and Gonska, Tanja and Greenfield, Jerry R and Leung, Daniel H and Lim, Adeline Y L and Moran, Antoinette and Prentice, Bernadette J and Putman, Melissa S and Trotter, Michael and Tullis, Elizabeth and Westall, Glen P and Verge, Charles F and Wainwright, Claire E and Ooi, Chee Y and SHIFT Symposium 2021, SHIFT Symposium 2021},
  title = {SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium},
  journal = {Pediatric Pulmonology},
  year = {2024},
  volume = {59},
  number = {6},
  pages = {1661--1676},
  doi = {10.1002/ppul.26970}
}
Kostenlos starten →